VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
- Resource Type
- Source
- Annals of Oncology. 34:124-125
- Subject
Oncology Hematology - Language
- ISSN
- 0923-7534